Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash from Financing Activities (2020 - 2025)

Gain Therapeutics has reported Cash from Financing Activities over the past 6 years, most recently at $16.6 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $16.6 million for Q4 2025, up 615.62% from a year ago — trailing twelve months through Dec 2025 was $28.4 million (up 118.63% YoY), and the annual figure for FY2025 was $28.4 million, up 118.63%.
  • Cash from Financing Activities for Q4 2025 was $16.6 million at Gain Therapeutics, up from $7.0 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for GANX hit a ceiling of $42.0 million in Q1 2021 and a floor of -$213795.0 in Q2 2021.
  • Median Cash from Financing Activities over the past 5 years was $808678.0 (2024), compared with a mean of $5.0 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 1925.72% in 2021 and later surged 161115.26% in 2023.
  • Gain Therapeutics' Cash from Financing Activities stood at -$9735.0 in 2021, then plummeted by 121.69% to -$21582.0 in 2022, then soared by 44398.94% to $9.6 million in 2023, then plummeted by 75.81% to $2.3 million in 2024, then skyrocketed by 615.62% to $16.6 million in 2025.
  • The last three reported values for Cash from Financing Activities were $16.6 million (Q4 2025), $7.0 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.